Literature DB >> 3053890

Cellular immune response to hepatitis B virus antigens. An overview.

C Ferrari1, A Penna, A DegliAntoni, F Fiaccadori.   

Abstract

It has been suggested that the cellular immune response to HBV antigens is responsible for hepatocellular injury in acute and chronic hepatitis B. However, definitive immunological studies have so far been hampered by the lack of appropriate model systems to study HBV antigen-specific T cells. The availability of highly purified and recombinant HBV antigens and of experimental techniques to maintain in continuous growth antigen-specific T cells derived not only from the peripheral blood but also from the liver should allow a better understanding of the fine immunopathogenetical mechanisms involved in viral clearance and liver damage. Whether some important biological characteristics of HBV antigens described in the mouse system, such as the high immunogenicity of the pre-S antigens and the capacity of the nucleocapsid of HBV to be a T cell-dependent and -independent antigen, are relevant to the immunopathogenesis of liver damage during natural HBV infection in man remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053890     DOI: 10.1016/s0168-8278(88)80503-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

Authors:  A J Demetris; S Todo; D H Van Thiel; J J Fung; Y Iwaki; G Sysyn; W Ming; J Trager; T E Starzl
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

3.  Trans-activation of HLA-DR gene by hepatitis B virus X gene product.

Authors:  K Q Hu; J M Vierling; A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  In vitro amplification of hepatitis B virus sequences from liver tumour DNA and from paraffin wax embedded tissues using the polymerase chain reaction.

Authors:  Y M Lo; W Z Mehal; K A Fleming
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

Review 5.  Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate.

Authors:  H Bécheur; D Valla; M A Loriot; A Attar; F Bloch; J P Petite
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

6.  Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers.

Authors:  T Wakita; S Kakumu; M Shibata; K Yoshioka; Y Ito; T Shinagawa; T Ishikawa; M Takayanagi; T Morishima
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

7.  Electron microscopic study of hepatitis B virus-associated antigens on the infected liver cell membrane in relation to analysis of immune target antigens in chronic hepatitis B.

Authors:  T Saito; T Kamimura; M Ishibashi; H Shinzawa; T Takahashi
Journal:  Gastroenterol Jpn       Date:  1992-12

8.  Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis.

Authors:  S Kakumu; T Shinagawa; T Ishikawa; K Yoshioka; T Wakita; N Ida
Journal:  Gastroenterol Jpn       Date:  1993-02

9.  Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide.

Authors:  M W Pride; H Shi; J M Anchin; D S Linthicum; P T LoVerde; A Thakur; Y Thanavala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.

Authors:  M C Jung; H M Diepolder; U Spengler; E A Wierenga; R Zachoval; R M Hoffmann; D Eichenlaub; G Frösner; H Will; G R Pape
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.